My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

24.74 +0.84 (+3.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
The Analyst Verdict: Travere Therapeutics In The Eyes Of 9 Experts
 
Via Benzinga
Travere Shares Are Trading Higher Wednesday: What's Going On?
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Daktronics, Potbelly, CoreWeave, GameStop And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Preview: Travere Therapeutics
 
Via Benzinga
Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High
Shares shot higher Wednesday after the FDA eliminated a key step to a new approval for its drug. 
Via Investor's Business Daily
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application
Via Stocktwits
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing. 
Via Benzinga
Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch
The company has made a name for itself with a drug that treats a progressive kidney condition. 
Via Investor's Business Daily
Nvidia To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Travere Therapeutics's Earnings: A Preview
 
Via Benzinga
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
Viking Global Dumps UnitedHealth, Loads Up On Disney, McDonald's, JPMorgan, AMD In Q2 Shake-Up
Via Benzinga
Travere Therapeutics Inc (NASDAQ:TVTX) Surpasses Q2 2025 Expectations with Strong Revenue Growth and Narrower Loss
Travere Therapeutics (TVTX) reported strong Q2 2025 results, beating revenue and earnings estimates, driven by FILSPARI sales and milestone payments. Shares rose 2.3% post-earnings. 
Via Chartmill
Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews
 
Via Benzinga
7 Analysts Assess Travere Therapeutics: What You Need To Know
 
Via Benzinga
Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why
Analysts are still bullish on the company's chances of being the first to win approval for an FSGS drug. 
Via Investor's Business Daily
Topics Government
Top movers in Friday's pre-market session
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries
Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Thursday's after hours session: top gainers and losers
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Is TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) following the Minervini trend for explosive growth?
Should you consider TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) for high growth investing? A fundamental and technical analysis of (NASDAQ:TVTX). 
Via Chartmill
Assessing Travere Therapeutics: Insights From 8 Financial Analysts
 
Via Benzinga
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.